Brief: Lisata Therapeutics Announces Outcome Of Interim Futility Analysis For Its Phase 2B Trial Of LSTA1 In Metastatic Pancreatic Ductal Adenocarcinoma
06/09/2023 16:19
Sept 6 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS ANNOUNCES OUTCOME OF INTERIM FUTILITY
ANALYSIS FOR ITS PHASE 2B ASCEND TRIAL OF LSTA1 IN METASTATIC
PANCREATIC DUCTAL ADENOCARCINOMA
* LISATA THERAPEUTICS INC - ASCEND TRIAL WILL CONTINUE AS
PLANNED
WITHOUT MODIFICATION
* LISATA THERAPEUTICS INC - ASCEND CONTINUES TO ENROLL AT A
RAPID
PACE AND WE AFFIRM OUR PROJECTION OF LAST PATIENT IN DURING
FIRST HALF OF 2024
Source text for Eikon: ID:nGNX9qtJN7
Further company coverage: LSTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal